Everything you need to know about TMS for Smoking Cessation: How Deep Brain Stimulation Targets Nicotine Addiction — how it works, what it costs, and how to find a provider who actually knows what they're doing.

Tobacco smoking remains the leading preventable cause of death in the United States, responsible for approximately 480,000 deaths annually. Despite widespread awareness of the health risks, approximately 28.3 million Americans continue to smoke, and the majority of those who attempt to quit will relapse within a week. Nicotine replacement therapy, varenicline (Chantix), bupropion (Wellbutrin), and behavioral counseling all have proven efficacy, but even in combination, they leave a substantial proportion of smokers unable to achieve lasting abstinence. The FDA clearance of deep transcranial magnetic stimulation (Deep TMS) for smoking cessation represents a fundamentally new approach — one that targets the neurobiological circuitry of addiction rather than addressing nicotine pharmacology alone.

What You’ll Learn

• How nicotine addiction affects the mesolimbic reward pathway and prefrontal cortex
• Why the insula is a key target for TMS in smoking cessation
• What the BrainsWay FDA clearance trial showed about quit rates
• How Deep TMS compares to medications like varenicline
• What the standard Deep TMS smoking cessation protocol looks like

The Neuroscience of Nicotine Addiction

Nicotine addiction is not simply a matter of habit or willpower — it is a chronic relapsing brain disorder with measurable neurobiological foundations.

When nicotine enters the brain, it binds to nicotinic acetylcholine receptors (nAChRs), triggering the release of dopamine in the mesolimbic reward pathway — the same neural circuitry activated by food, sex, and other natural rewards. The resulting dopamine surge in the nucleus accumbens (NAc) and ventral tegmental area (VTA) creates the subjective experience of pleasure and reward that reinforces smoking behavior.

Over time, with chronic nicotine exposure, the brain adapts:

• Dopamine receptor availability decreases, requiring more nicotine to achieve the same reward
• Cue-reactivity strengthens: Brain regions associated with conditioned reward (the hippocampus, amygdala, and orbitofrontal cortex) develop hyperactive responses to smoking-related cues (the smell of cigarettes, the feel of a pack, after a meal)
• Prefrontal regulatory function declines: The dorsolateral prefrontal cortex (dlPFC), responsible for decision-making and impulse control, becomes less effective at inhibiting smoking urges

This last change is critical: the prefrontal cortex normally allows us to weigh the long-term consequences of our actions against immediate impulses. When prefrontal function is compromised by chronic nicotine exposure, the brain’s reward systems override rational decision-making, perpetuating addiction.

Deep TMS for Smoking Cessation: The Science

Deep TMS for smoking cessation uses the BrainsWay H-coil system to stimulate deeper brain structures than standard TMS coils can reach. The primary targets are the dorsolateral prefrontal cortex (dlPFC) and the insula — a deep brain region that is critically involved in addiction.

The insula has emerged as a key structure in addiction neuroscience. It plays a central role in interoception (awareness of internal bodily states), craving, and decision-making related to substance use. Neuroimaging studies consistently show that the insula is hyperactive in smokers and that smoking cessation is associated with reduced insula activity. Damage to the insula (from strokes or injuries) has been associated with sudden, effortless smoking cessation — an observation that has profoundly influenced addiction neuroscience.

By targeting the insula and the prefrontal cortex with deep TMS, the treatment aims to:

1. Reduce cravings by modulating insula activity
2. Strengthen prefrontal regulatory function, enhancing the brain’s capacity to resist urges
3. Disrupt the conditioned reward associations that make smoking cues so powerfully triggering

FDA Clearance and Clinical Evidence

In 2014, the BrainsWay Deep TMS system received FDA clearance for smoking cessation in adults who want to quit smoking. This was a landmark regulatory decision — the first time an electromagnetic brain stimulation device received FDA clearance for an addiction indication.

The pivotal clinical trial supporting FDA clearance was a randomized, sham-controlled study involving 262 smokers who were motivated to quit. Participants received 16 sessions of active or sham Deep TMS over five weeks, combined with brief counseling. The results were striking:

• Continuous quit rate at week 16: 28.4% for active TMS vs. 11.9% for sham
• Point prevalence quit rate at week 16: 33.7% for active TMS vs. 13.5% for sham
• Smoking reduction: Active TMS participants reduced their daily cigarette consumption by an average of 40%

These quit rates substantially exceed those typically seen with nicotine replacement therapy (approximately 15-20% at six months) and are comparable to or better than varenicline rates in similar populations.

A subsequent multicenter study published in World Neurosurgery replicated these findings, with active Deep TMS producing significantly higher quit rates than sham treatment at both 3-month and 6-month follow-ups.

The Treatment Protocol

The standard Deep TMS protocol for smoking cessation involves:

• 16 treatment sessions over 5 weeks (approximately 3 sessions per week in the first two weeks, followed by once-weekly sessions)
• Each session lasts approximately 20 minutes
• The coil is positioned over the left and right prefrontal cortex (bilateral stimulation)
• Treatment is performed in an outpatient setting without anesthesia

The protocol is designed to be compatible with other cessation methods. Patients may continue using nicotine replacement therapy or other medications during TMS treatment. In fact, some clinicians advocate for combining TMS with pharmacological and behavioral support for maximum effect.

Who Is a Candidate?

Deep TMS for smoking cessation is appropriate for:

• Adult smokers who have previously attempted to quit and relapsed
• Smokers who have not responded to or cannot tolerate medications such as varenicline or bupropion
• Smokers seeking a non-pharmacological adjunct to their quit attempt
• Individuals without contraindications to TMS (no epilepsy, no metal implants in the head, no active psychotic disorder)

It is important to note that TMS for smoking cessation requires genuine motivation to quit. Like all cessation methods, it works best when combined with behavioral counseling and genuine commitment to change.

Why TMS Is a Game-Changer for Addiction Treatment

The clearance of TMS for smoking cessation represents a paradigm shift in addiction medicine. For decades, treatment options were limited to medications targeting nicotine pharmacology and behavioral counseling. TMS introduces a third modality: direct neuromodulation of the brain circuits underlying addiction.

This approach is not specific to smoking. Researchers are actively investigating TMS for alcohol use disorder, cocaine addiction, opioid use disorder, and cannabis use disorder. While this research is still in early stages, the smoking cessation data provide proof of concept that TMS can meaningfully reduce addictive behaviors by addressing their neurological roots.

For smokers who have tried everything and failed, Deep TMS offers a scientifically grounded, FDA-cleared option that targets the craving, reward, and regulatory circuits that have made quitting so difficult.